Back to top
more

Option Care Health (OPCH)

(Delayed Data from NSDQ)

$28.10 USD

28.10
1,410,018

-0.16 (-0.57%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $28.10 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Urmimala Biswas headshot

3 MedTech Sectors Benefiting Despite COVID-19 Resurgence

by Urmimala Biswas

Here we discuss three major subsectors of MedTech and some of their constituent stocks for which COVID-19 has opened up enormous growth prospects.

Zacks Equity Research

Can Option Care (OPCH) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Option Care (OPCH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Recent Price Trend in Option Care (OPCH) is Your Friend, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Option Care (OPCH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

New Strong Buy Stocks for August 16th

by Zacks Equity Research

CVLG, DDS, MHO, OPCH, and TUP have been added to the Zacks Rank #1 (Strong Buy) List on August 16, 2021.

Zacks Equity Research

Option Care (OPCH) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Option Care (OPCH) delivered earnings and revenue surprises of 125.00% and 9.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Option Care (OPCH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Option Care (OPCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Option Care (OPCH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Option Care (OPCH) delivered earnings and revenue surprises of -200.00% and 0.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Option Care Health (OPCH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (OPCH) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Option Care (OPCH) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Option Care (OPCH) delivered earnings and revenue surprises of 42.86% and 0.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Option Care (OPCH) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Option Care (OPCH) closed at $19.54 in the latest trading session, marking a -1.19% move from the prior day.

Zacks Equity Research

What's in Store for Fulgent Genetics (FLGT) in Q4 Earnings?

by Zacks Equity Research

We expect strong demand for Fulgent Genetics' (FLGT) end-to-end tests for COVID-19 to have continued through the fourth quarter.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect weak segmental performance.

Zacks Equity Research

Option Care (OPCH) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Option Care (OPCH) closed at $18.97, marking a +0.58% move from the previous day.

Zacks Equity Research

Is Option Care Health (OPCH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (OPCH) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Owens & Minor (OMI) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

We expect the strength in demand for Owens & Minor's (OMI) PPEs to have continued through the fourth quarter.

Zacks Equity Research

Option Care (OPCH) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Option Care (OPCH) closed the most recent trading day at $19.86, moving +0.2% from the previous trading session.

Zacks Equity Research

Lower Bulk Purchases May Weigh on Medtronic (MDT) Q3 Earnings

by Zacks Equity Research

Medtronic's (MDT) diabetes care, robotics surgery and neuromodulation lines are expected to have performed well in Q3.

Zacks Equity Research

Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) fourth-quarter results are likely to reflect gains from the Global Healthcare and Life Sciences segment.

Zacks Equity Research

OPKO Health (OPK) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

OPKO Health's (OPK) fourth-quarter results are likely to reflect solid performance from Services and Products segment and RAYALDEE.

Zacks Equity Research

Invitae (NVTA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Invitae's (NVTA) fourth-quarter results are likely to reflect strength in genetic testing.

Zacks Equity Research

Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?

by Zacks Equity Research

Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).

Zacks Equity Research

Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q4.

Zacks Equity Research

Exact Sciences (EXAS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.

Zacks Equity Research

What's in Store for Pacific Biosciences' (PACB) Q4 Earnings?

by Zacks Equity Research

Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.

Zacks Equity Research

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.